Efficacy of N-Acetyl cysteine in patients with autism spectrum disorder

Phase 3

Recruiting

Conditions: Autism spectrum disorder.
Childhood autism
F84.0

Registration Number: IRCT20190714044199N1

Lead Sponsor: Medical Science University of Mashhad

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 66

Inclusion Criteria

Autism spectrum disorder (ASD) patients aging between 3 to 12
Having parental informed consent
IQ score greater than 50 based on Wildland Test
Receiving risperidone therapy for at least one month
Lack of clear organic disease (based on family history and medical records) Clear organic causes include visual and hearing impairment, seizures, trauma cycles, chronic or acute medical disorder, and brain dysfunction.
Psychiatric disorders including Toure's syndrome, Fragile X syndrome, schizophrenia, Attension deficit hyperactivity disorder (ADHD) based on structured psychiatric interview conducted by pediatric psychiatrist

Exclusion Criteria

If the parents do not cooperate for any reason after entering the study 2- 3-
Use of any psychotropic drugs other than risperidone
Any unbearable or life-threatening drug side effect or any other illness that requires medication which may interfere with results of this study.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of ASD was evaluated by CARS questionnaire. Timepoint: Baseline, 5 and 10 weeks after baseline. Method of measurement: CARS questionnaires.;Severity, drug response and drug adverse effects was evaluated by CGI questionnaire. Timepoint: Baseline, 5 and 10 weeks after baseline. Method of measurement: CGI questionnaires.

Secondary Outcome Measures